Moderna: MRNA earnings report indicated $2.84 in EPS and $1.9B in revenue. The company will supply a Covid-19 booster vaccine to Switzerland. Oppenheimer's Hartaj Singh weighs in and says that they have an outperform rating on the stock with a $206 price target.
Morning Trade Live
06 May 2021
SHARE
Trading 360
23 Feb 2022
The Watch List
08 Feb 2022
Trading 360
28 Apr 2022
Trading 360
09 Feb 2022
Market On Close
24 Feb 2022
The Watch List
28 Mar 2022